Besifloxacin: A novel anti-infective for the treatment of bacterial conjunctivitis

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 215-225

  Comstock, Timothy L ^a   Karpecki, Paul M ^b   Morris, Timothy W ^a   Zhang, Jin Zhong ^a  

^a BAUSCH AND LOMB   (United States)

^b Koffler Vision Group   (United States)

Author keywords

Bacterial conjunctivitis; Besifloxacin; Besivance; Conjunctivitis; Fluoroquinolones

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BESIFLOXACIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PLACEBO; QUINOLONE DERIVATIVE; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BLURRED VISION; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; EYE IRRITATION; EYE PAIN; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OCULAR PRURITUS; REVIEW; SINGLE DRUG DOSE; VIRAL CONJUNCTIVITIS;

EID: 77953467084     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s9604     Document Type: Review

References (30)

1. American Optometric Association. Care of the patient with conjunctivitis. Optometric clinical practice guideline. http://www.aoa.org/documents/ CPG-11.pdf. Accessed September 22, 2009.
2. Brook I. Ocular infections due to anaerobic bacteria in children. J Pediatr Ophthalmol Strabismus. 2008;45(2):78-84.
3. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med. 2008;75(7):507-512.
4. Hussar DA. New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine. J Am Pharm Assoc (2003). 2009;49(4): 570-574.
5. Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in South Florida. Ophthalmology. 2008;115(1):51-56.
6. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2006;2:CD001211.
7. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008;145(6):951-958.
8. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998;57(4):735-746.
9. Diamant JI, Hwang DG. Therapy for bacterial conjunctivitis. Ophthalmol Clin North Am. 1999;12(1):15-20.
10. Arnold DR, Granvil CP, Ward KW, Proksch JW. Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1): 105-110.
11. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3(6):359-371.
12. Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009;63(3): 443-450.
13. Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg. 2008;34(5):814-818.
14. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106(7):1313-1318.
15. Besivance [package insert]. Tampa, FL: Bausch and Lomb Inc: 2009.
16. Protzko E, Bowman L, Abelson M, et al. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48(8):3425-3429.
17. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12(1):147-179.
18. Blondeau JM, Borsos S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother. 2007;19(2):146-151.
19. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25(4):335-344.
20. Ward KW, Lepage JF, Driot JY. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther. 2007;23(3):243-256.
21. Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53(8):3552-3560.
22. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for new ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49(Suppl 2):S79-S78.
23. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(3):1159-1169.
24. Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31(3):514-526.
25. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116(9):1615-1623.e1.
26. Data on file. Bausch and Lomb. Rochester, NY.
27. Paterno MR, Comstock TL, Lynch JA, Usner DW. Besifloxacin ophthalmic suspension 0.6% is safe and well tolerated in patients with bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2009;50:E-Abstract 2674.
28. Comstock TL, Paterno MR, Lynch JA, DeCory HH, Usner DW. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in pediatric patients with bacterial conjunctivitis. Optometry. 2009;80(6): 296-297.
29. Zhang JZ, Krenzer KL, López FJ, Ward KW. Comparative effects of besifloxacin and other fluoroquinolones on corneal reepitheliazation in the rabbit. Presented at: 5th International Conference on Ocular Infections; February 18-21, 2010; Palm Beach, FL.
30. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.